Molecular Oncology, Vol 14, Iss 3, Pp 490-503 (2020) Molecular Oncology, 14, 490-503. John Wiley & Sons Ltd. Kruger, D T, Jansen, M P H M, Konings, I R H M, Dercksen, W M, Jager, A, Oulad Hadj, J, Sleijfer, S, Martens, J W M & Boven, E 2020, ' High ctDNA molecule numbers relate with poor outcome in advanced ER+, HER2-postmenopausal breast cancer patients treated with everolimus and exemestane ', Molecular oncology, vol. 14, no. 3, pp. 490-503 . https://doi.org/10.1002/1878-0261.12617 Molecular Oncology Molecular oncology, 14(3), 490-503. Elsevier
Martin, M, Holmes, F A, Ejlertsen, B, Delaloge, S, Moy, B, Iwata, H, von Minckwitz, G, Chia, S K L, Mansi, J, Barrios, C H, Gnant, M, Tomašević, Z, Denduluri, N, Šeparović, R, Gokmen, E, Bashford, A, Ruiz Borrego, M, Kim, S-B, Jakobsen, E H, Ciceniene, A, Inoue, K, Overkamp, F, Heijns, J B, Armstrong, A C, Link, J S, Joy, A A, Bryce, R, Wong, A, Moran, S, Yao, B, Xu, F, Auerbach, A, Buyse, M, Chan, A, Langkjer, S T & ExteNET Study Group (Sven Tyge Langkjer; member) 2017, ' Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial. ', The Lancet Oncology, vol. 18, no. 12, pp. 1688-1700 . https://doi.org/10.1016/S1470-2045(17)30717-9 ExteNET Study Group 2017, ' Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET) : 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial ', The Lancet Oncology, vol. 18, no. 12, pp. 1688-1700 . https://doi.org/10.1016/S1470-2045(17)30717-9